Haemophilia B clinical trials

Explore recruiting haemophilia b clinical trials.

Recruiting haemophilia b studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Haemophilia B trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Phase III, open-label, single-dose, multi-center multinational trial investigating a serotype 5 adeno-associated viral vector containing the Padua variant of a codon-optimized human factor IX gene (AAV5-hFIXco-Padua, AMT-061) administered to adult subjects with severe or moderately severe hemophilia B

Belgium, Netherlands, Germany, Ireland, Denmark, Sweden

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase I/IIb extension study assessing the long-term safety and efficacy of an adeno-associated viral vector containing a codon-optimized human factor IX gene (AAV5-hFIX) previously administered to adult patients with severe or moderately severe haemophilia B during the CT-AMT-060-01 Phase I/II study.

Netherlands, Germany

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

An Extension Study Assessing the Long-term Safety and Efficacy of Etranacogene Dezaparvovec (CSL222) Previously Administered to Adult Male Subjects with Hemophilia B

Netherlands, Denmark, Belgium, Germany, Ireland, Sweden

Phase II and Phase III (Integrated) EU CTIS Study details

Efficacy and Safety of Concizumab prophylaxis in patients with haemophilia A or B without inhibitors

Estonia, Portugal, Spain, Italy, Germany, Denmark +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

An 18-month low-interventional prospective, multicentre study to assess joint outcomes in patients with haemophilia A or B on prophylaxis with efmoroctocog alfa or eftrenonacog alfa

Hungary, Ireland, Czechia, Italy, Croatia, Spain +4 more

Therapeutic use (Phase IV) EU CTIS Study details

Efficacy and Safety of Concizumab prophylaxis in patients with haemophilia A or B with inhibitors

Denmark, France, Croatia, Poland, Portugal, Italy +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Haemophilia B trials by city

Haemophilia B in Toronto Haemophilia B in Vancouver Haemophilia B in Montreal Haemophilia B in Calgary Haemophilia B in Edmonton Haemophilia B in Ottawa Haemophilia B in Winnipeg Haemophilia B in Quebec City Haemophilia B in Hamilton Haemophilia B in Kitchener Haemophilia B in London Haemophilia B in Halifax Haemophilia B in New York Haemophilia B in Los Angeles Haemophilia B in Chicago Haemophilia B in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease